Clinical Trials Browser

Completed × Myelodysplastic Syndromes × durvalumab × Clear all

NCT02775903 2023-02-28

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Phase 2 Completed

213 enrolled 35 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute